compiling the suspected adverse event reports referred to in Article 76(2), evaluating them, where necessary, and recording them in the pharmacovigilance database;
na teagmhais dhíobhálacha amhrasta dá dtagraítear in Airteagal 76(2) a thiomsú, meastóireacht a dhéanamh orthu, más gá, agus iad a thaifeadadh sa bhunachar sonraí faireachais cógas;